The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk

The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk

March 9, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270The ACR Supports the Safe Adoption of Biosimilars in U.S.
A top priority for the American College of Rheumatology (ACR) is the safe adoption of biosimilars. The ACR Board of Directors recently approved a revised position statement on biosimilars during the February board meeting that updates and clarifies the ACR’s positions on extrapolation, substitution, notification and labeling. The original position statement was released in March 2015 shortly after the U.S. Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio) in the U.S. Subsequently, the ACR applauded the FDA draft guidance requiring separate, distinct names for biosimilars and biologic therapies, which occurred in August 2015.

You Might Also Like
  • FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA
  • FDA Advisory Committee Votes in Favor of Romosozumab Approval
  • Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise
Also By This Author
  • Celecoxib & Cardiovascular Death: NSAID Safety Under Review

On Feb. 9, 2016, the FDA’s Arthritis Advisory Committee held a public meeting to review the license application of CT-P13 (a proposed infliximab [Remicade] biosimilar). At the time, the ACR provided recommendations for policy guidelines to implement as the committee decides whether to license additional biosimilars for sale in the U.S.1 If approved, CT-P13 would be the first biosimilar for the possible treatment of rheumatic diseases, including rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Speaking on behalf of the ACR at the hearing, Angus Worthing, MD, FACP, FACR, a practicing rheumatologist and member of the ACR Government Affairs Committee, discussed how the collection of clinical data should ensure safety and efficacy prior to approval, as well as the collection of long-term, post-marketing studies of approved biosimilars to monitor adverse events. He also reiterated the ACR’s position that distinct biosimilar names are necessary to ensure correct prescribing and dispensing, enable post-marketing monitoring of individual drugs, and increase prescriber confidence and enhanced market uptake.

Dr. Worthing advised the FDA to be cautious when it considers approving the extrapolation of biosimilar products for indications in which the reference biologic has already been approved in the absence of safety data specific to the individual biosimilar agent and a particular patient population. He called for FDA labeling to indicate whether a particular biosimilar product is interchangeable with its reference biologic and for the FDA to list all indications for which the biosimilar is approved. Additionally, he recommended that the FDA specify whether supporting clinical data for usage was derived from studies of the biosimilar or its reference biologic.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Once Daily Tofacitinib Approved
In other news, the FDA has approved 11 mg extended-release tablets of tofacitinib citrate for once-daily administration to treat moderate to severe RA in patients who are intolerant of or have had an inadequate response to methotrexate.2

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: American College of Rheumatology, Biosimilars, FDA, Food and Drug Administration, infliximab, romosozumab, Tofacitinib, tofacitinib citrate

You Might Also Like:
  • FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA
  • FDA Advisory Committee Votes in Favor of Romosozumab Approval
  • Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise
  • Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)